Lungs News and Research

RSS

Legionnaires' disease kills a 66 year old

There has been a death with Legionnaire’s disease in Doncaster. This disease is caused by bacteria that infects people when they breathe in infested water droplets, such as spray drifts from cooling towers.

3 Jun 2010

Two-day workshop on sickle cell trait

Scientists from across the nation will gather June 3-4 to discuss what is known about sickle cell trait and the potential health implications related to this genetic blood condition. "Framing the Research Agenda for Sickle Cell Trait" will examine the ethical, legal, social, and public health impacts of the blood condition.

3 Jun 2010

Discovery reveals a new approach to target cancer

Researchers at the University of Pittsburgh Cancer Institute (UPCI) and the School of Medicine have discovered that inhibiting a key molecule in a DNA repair pathway could provide the means to make cancer cells more sensitive to radiation therapy while protecting healthy cells.

3 Jun 2010

Advanced CT scanner allows rapid organ imaging, reduces radiation exposure

UT Southwestern Medical Center is the first site in North Texas to launch the next generation in CT scanners, which allow doctors to image an entire organ in less than a second or track blood flow through the brain or to a tumor - all with less radiation exposure to patients.

3 Jun 2010

Radiation therapy may not improve chances of survival for bladder cancer patients: Study

In the largest study to date of a rare and deadly form of bladder cancer, researchers at Henry Ford Hospital in Detroit found radiation therapy may not improve a patient's chances for survival.

3 Jun 2010

Academic detailing technique may help doctors follow treatment guidelines

Researchers often get frustrated when doctors fail to adopt treatment guidelines backed by the best evidence-based research.

3 Jun 2010

In 2008, 63% of cancer deaths were in developing countries

By 2030, cancer could claim the lives of 13.3 million annually, almost double the number of patients who died from the illness in 2008, the U.N.'s International Agency for Research on Cancer (IARC) said Tuesday, Agence France-Presse reports.

3 Jun 2010

CPAP treatment may be a better option for preterm infants

A national study involving a UT Southwestern Medical Center neonatologist provides new insight into how much oxygen preterm infants should receive as well as the optimal way to deliver it to them.

3 Jun 2010

Biomoda, Obio sign MOU to establish CLIA-certified clinical laboratory in Ohio

Cancer diagnostics company Biomoda, Inc. and Obio, a corporation formed to pursue public and private funding for cancer research in Ohio, signed a memorandum of understanding to establish a CLIA-certified Biomoda clinical laboratory in Ohio to support ongoing research and development on Biomoda's porphyrin-based assay for the detection of early-stage cancer.

2 Jun 2010

Predictive biomarker for patients with NSCLC

The era of one-size-fits-all medicine will eventually be history; after all it is no news that drugs and treatments do not work the same for everyone. For patients with nonsmall cell lung cancer, a lung cancer that kills approximately 1 million people annually, the treatment currently available is basically the same for all patients, despite the fact that some patients may respond to treatment while others may not.

2 Jun 2010

Study demonstrates diagnostic, economic benefits of AABT for lung cancer patients

Oncimmune LLC, maker of EarlyCDT-Lung, a simple blood test that aids physicians in risk assessment and the early detection of lung cancer, today announced validation study results demonstrating the diagnostic and economic benefits of a standardized and reproducible autoantibody laboratory test that may significantly improve the prognosis for lung cancer patients.

2 Jun 2010

Oncimmune develops new blood test to aid early detection of cancer

The University of Nottingham spin-out company, Oncimmune Ltd, has developed a ground breaking blood test which will aid the detection of cancer as much as five years earlier than current testing methods such as mammography and CT scans. Physicians will know the result of their patient's test within one week of sending in a blood sample to Oncimmune.

2 Jun 2010

Mayo Clinic study examines benefits of surgical treatment of kidney cancer

When kidney cancer spreads to other body parts, patients usually receive a poor prognosis. A new Mayo Clinic study examined the benefits of surgical treatment of kidney cancer, specifically renal cell carcinoma, and how patients saw improved prognosis of their cancer.

2 Jun 2010

CCL5 protein plays protective role against Mycobacterium tuberculosis: New research

Ohio scientists hope to counter the re-emerging threat of tuberculosis with help from proteins from our bodies. In a research report published in the June 2010 print issue of the Journal of Leukocyte Biology, scientists show how the protein CCL5 plays a protective role in helping the body ward off this contagious, airborne disease in the early stages of infection.

2 Jun 2010

Proton therapy offers life-changing benefits to children with cancer

The Children's Hospital of Philadelphia announces the availability of proton therapy, a precise form of cancer radiation that offers potentially life-changing benefits to children with brain tumors and other solid tumors. The Hospital's Cancer Center has recently begun using proton treatment at the new Roberts Proton Therapy Center, a cutting-edge radiation oncology facility located across the street from Children's Hospital in Penn Medicine's Perelman Center for Advanced Medicine.

2 Jun 2010

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.

2 Jun 2010

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

AMRI announced today that on-going results from its Phase I clinical study on its novel tubulin inhibitor, ALB 109564(a), were published on the website of the American Society of Clinical Oncology (abstract.asco.org/alb). These results indicate that ALB 109564(a) is well tolerated at the doses tested and shows preliminary evidence of clinical activity in disease types not typically treated with approved vinca alkaloids.

2 Jun 2010

Europe spends just 5% of total cancer research funds on metastases

On average, about five percent of total cancer research funding is spent on investigating metastases (the spread of cancer cells around the body) in Europe, yet metastatic disease is the direct or indirect cause of 90 percent of all cancer deaths, according to an editorial in the European Journal of Cancer (EJC).

1 Jun 2010

Centocor Ortho Biotech acquires RespiVert

Centocor Ortho Biotech Inc. today announced that it has acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases. The company's lead compounds, RV-568 and RV-1088, narrow spectrum kinase inhibitors with a unique profile of anti-inflammatory activities, are progressing into clinical development as potential first-in-class treatments for moderate to severe asthma, Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF).

1 Jun 2010

RNAi therapy shuts down gene critical to RSV, prevents virus replication

John DeVincenzo, MD, professor and researcher in the Departments of Pediatrics and Molecular Sciences at the University of Tennessee Health Science Center (UTHSC), has proven for the first time that a totally new concept in drug design can be used to treat human disease. Dr. DeVincenzo, who also serves as a children's infectious diseases specialist at Le Bonheur Children's Hospital, conducted his study at the Children's Foundation Research Center, a UT Health Science Center partner located at Le Bonheur.

29 May 2010